Efficacy of salvage chemotherapy in diffuse large B cell lymphoma with primary treatment failure according to putative cell of origin. Issue 4 (21st March 2019)

• Record Type: Journal Article
• Authors: Badar, Talha; Hamadani, Mehdi; Bachanova, Veronika; Maddocks, Kami J.; Umyarova, Elvira; Chavez, Julio C.; Epperla, Narendranath; Chhabra, Saurabh; Xavier, Ana C.; Karmali, Reem; Salhab, Mohammed; Reddy, Nishitha; Glenn, Martha J.; Hernandez-Ilizaliturri, Francisco J.; Flowers, Christopher R.; Evens, Andrew M; Zhou, Zheng; Lansigan, Frederick; Barta, Stefan K.; Cohen, Jonathon B; Fenske, Timothy S.; Costa, Luciano J.
• Is Part Of: Leukemia & lymphoma. Volume 60:Issue 4(2019)
• Page Start: 940
• Page End: 946
• Publication Date: 2019-03-21
• Subjects: Refractory diffuse large B-cell lymphoma -- putative cell-of-origin -- germinal center B-cell like DLBCL; Leukemia -- Periodicals; Lymphomas -- Periodicals; 616.99419
• DOI: 10.1080/10428194.2018.1515944
• Languages: English
• ISSNs: 1042-8194

Abstract

Abstract: We evaluated outcome of 235 primary treatment failure (PTF) diffuse large B-cell lymphoma (DLBCL) patients based on salvage chemotherapy regimen and putative cell-of-origin (COO). Patients were divided into two groups; group A ( n = 38) received high-dose cytarabine containing regimen, either DHAP or ESHAP. Patients in group B ( n = 197) received ifosfamide, carboplatin, and etoposide (ICE) +/− rituximab. No difference in overall response rates (CR + PR) was observed based on salvage chemotherapy regimen and COO. After adjustment for the presence of ultra high-risk features, overall survival of germinal center B-cell like (GCB) DLBCL patients in group A was not significantly different from survival in group B (HR 0.86, 95% CI 0.46–1.60, p = .64). Similarly, within non-GCB DLBCL cohort, survival in group A was comparable to group B (HR 0.53, 95% CI 0.20–1.44, p = .21). We did not find an outcome difference between two commonly used salvage chemotherapy regimens in patients with PTF DLBCL based on COO.